Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Treace Medical Concepts's ROE % for the quarter that ended in Jun. 2026 was -87.62%. Treace Medical Concepts's PB Ratio for the quarter that ended in Jun. 2026 was 3.82.
Treace Medical Concepts's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -22.94%.
Treace Medical Concepts ROE % Adjusted to Book Value Related Terms
Treace Medical Concepts ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Treace Medical Concepts's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Treace Medical Concepts ROE % Adjusted to Book Value Chart
TMCI vs TLSI, SENS, SGHT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Treace Medical Concepts's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Treace Medical Concepts ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Treace Medical Concepts's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -22.94% mean?
Treace Medical Concepts (TMCI) has a ROE % Adjusted to Book Value of -22.94% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Treace Medical Concepts and its competitors.
Is Treace Medical Concepts' ROE % Adjusted to Book Value too high?
Treace Medical Concepts' current ROE % Adjusted to Book Value is -22.94%. Overall, Treace Medical Concepts has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Treace Medical Concepts' ROE % Adjusted to Book Value compare to TLSI and SENS?
Treace Medical Concepts' ROE % Adjusted to Book Value of -22.94% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Treace Medical Concepts and its competitors. Treace Medical Concepts's current ROE % Adjusted to Book Value is -22.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Treace Medical Concepts stock overvalued right now?
Based on GuruFocus' analysis, Treace Medical Concepts (TMCI) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.35, compared to a current price of $4.79 — trading 24.6% below its estimated fair value. The current ROE % Adjusted to Book Value is -22.94%. Treace Medical Concepts' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Treace Medical Concepts (TMCI), the current ROE % Adjusted to Book Value is -22.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Treace Medical Concepts (TMCI) Overvalued in 2026?
Based on GuruFocus' analysis, Treace Medical Concepts stock appears to be undervalued.
The current stock price of $4.79 is trading 24.6% below its estimated GF Value™ of $6.35.
GuruFocus considers Treace Medical Concepts to be Modestly Undervalued.
Key valuation signals for TMCI:
ROE % Adjusted to Book Value: -22.94%
GF Value™: $6.35 vs. price of $4.79 (24.6% below fair value)
No single metric tells the full story. See the TMCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
68GF Score
Get the complete analysis for TMCI
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMCI has been successfully added to your 
